BPIM
CRL icon

Brant Point Investment Management’s Charles River Laboratories CRL Stock Holding History

Brant Point Investment Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,936
Closed -$2.82M – 105
2023
Q4 		$2.82M Buy
11,936
+1,385
+13% +$272K 0.23% 79
2023
Q3 		$2.07M Sell
10,551
-3,586
-25% -$736K 0.19% 81
2023
Q2 		$2.97M Sell
14,137
-46
-0.3% -$9.15K 0.68% 55
2023
Q1 		$2.86M Sell
14,183
-5,098
-26% -$1.16M 0.48% 64
2022
Q4 		$4.2M Sell
19,281
-2,317
-11% -$506K 0.62% 45
2022
Q3 		$4.25M Buy
21,598
+6,500
+43% +$1.4M 0.62% 48
2022
Q2 		$3.23M Sell
15,098
-6,902
-31% -$1.69M 0.48% 56
2022
Q1 		$6.25M Buy
22,000
+6,904
+46% +$2.13M 0.71% 41
2021
Q4 		$5.69M Buy
15,096
+48
+0.3% +$18.6K 0.89% 47
2021
Q3 		$6.21M Buy
15,048
+48
+0.3% +$19.9K 0.54% 39
2021
Q2 		$5.55M Hold
15,000
– – 0.51% 53
2021
Q1 		$4.35M Hold
15,000
– – 0.47% 71
2020
Q4 		$3.75M Buy
15,000
+10,000
+200% +$2.38M 0.44% 75
2020
Q3 		$1.13M Hold
5,000
– – 0.1% 116
2020
Q2 		$872K Buy
+5,000
New +$798K 0.09% 112
2019
Q2 		– Sell
-19,800
Closed -$2.88M – 120
2019
Q1 		$2.88M Buy
+19,800
New +$2.6M 0.36% 70
2017
Q4 		– Sell
-38,800
Closed -$4.19M – 141
2017
Q3 		$4.19M Sell
38,800
-10,600
-21% -$1.09M 0.44% 61
2017
Q2 		$5M Sell
49,400
-18,700
-27% -$1.72M 0.61% 48
2017
Q1 		$6.13M Buy
+68,100
New +$5.78M 0.63% 38

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Brant Point Investment Management's CRL Position: Q1 2024 in Review

Brant Point Investment Management sold out of Charles River Laboratories (CRL) in Q1 2024, closing a stake of 11,936 shares — an estimated $2.82M sold.

Brant Point Investment Management first reported a position in CRL in Q1 2017 and held it in 19 quarters. The position peaked at $6.25M in Q1 2022. 676 funds tracked by Wall St. Rank hold CRL as of Q1 2024.

  • Brant Point Investment Management reported no remaining Charles River Laboratories position as of Q1 2024 after selling out during the quarter.
  • Brant Point Investment Management sold 11,936 Charles River Laboratories shares in Q1 2024, an estimated $2.82M.
  • Brant Point Investment Management first reported a position in Charles River Laboratories in Q1 2017 and held it in 19 quarters.
  • Brant Point Investment Management's Charles River Laboratories position peaked at $6.25M in Q1 2022.
  • 676 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2024.

Based on Brant Point Investment Management's 13F filing for Q1 2024, filed 14 May 2024.